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Abstract In transfected CHO cells constitutively active hista-
mine H2 receptors not only increase the basal cAMP level, but 
also enhance forskolin-induced cAMP production. The increased 
forskolin response was inhibited by inverse H2 agonists with 
potencies similar to those determined at basal levels. The 
modulation of the forskolin response was also observed after 
H2 receptor expression in HEK-293 and Sf9 cells or TSH 
receptor expression in COS-7 cells. The enhancement of 
forskolin-induced cAMP production seems to be a general 
characteristic of constitutively active Gs-coupled receptors and 
can be very useful to study inverse agonism at wild-type 
receptors. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Classical models of G-protein-coupled receptors (GPCRs) 
require agonist occupation of the receptor to activate signal 
transduction pathways. Nowadays, it is well documented that 
GPCRs can be spontaneously active and this agonist-inde-
pendent receptor activity is often referred to as constitutive 
receptor activity [1-5]. Inverse agonists reduce the constitutive 
GPCR activity, whereas neutral antagonists do not affect the 
basal GPCR activity. Constitutive activity was first shown for 
mutant GPCRs and has proved to be the mechanistic basis 
for several genetic diseases [6]. Moreover, a detailed under-
standing of constitutive GPCR activity will give better insights 
of agonist-induced GPCR activation [5]. Because of these im-
portant implications the phenomenon of constitutive GPCR 
activity and inverse agonism currently receives considerable 
attention [1-5]. 
To study inverse agonism GPCRs should possess a detect-
able level of constitutive activity. Constitutive activity of wild-
type receptors is generally low and inverse agonism is there-
fore often studied using constitutively active mutant (CAM) 
GPCRs. However, as a result of introduced mutations, the 
pharmacological behaviour of ligands can be seriously af-
fected [7,8]. For example, as a result of a single point muta-
tion in TM4 of the 8-opioid and n-opioid receptors antago-
nists became surprisingly full agonists [8]. Moreover, the 
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ß-blocker propranolol was reported to change from an inverse 
agonist at the wild-type ß2-adrenergic receptor [9] to a neutral 
antagonist at a constitutively active ß2-adrenergic receptor 
mutant [10]. In view of these findings the use of wild-type 
receptors in the study of inverse agonism is preferred. 
Recently, the use of highly sensitive reporter gene technol-
ogy has been introduced to observe constitutive activity of 
wild-type Gq-coupled receptors [11]. Similarly, modifications 
of the extracellular sodium concentration have been shown to 
increase the constitutive activity of bradykinin B2 [12], TSH 
[13] and LH receptor [13]. Moreover, overexpression of Gocq 
in NIH-3T3 cells results in a detectable constitutive activity of 
the coexpressed, wild-type muscarinic m3 receptor [14]. How-
ever, this latter approach is not always feasible. Overexpres-
sion of Gces in NG108-15 cells did not affect the constitutive 
activity of the ß2-adrenergic receptor [15], probably because 
Gocs is not the limiting factor in the signal transduction. 
Activation of Gs-coupled receptors and reconstitution of 
adenylyl cyclase isoenzymes with purified Ga s subunits are 
known to have a synergistic effect on the forskolin-induced 
adenylyl cyclase activation [16,17]. Consequently, constitu-
tively active Gs-coupled receptors can be anticipated to poten-
tiate forskolin responses by increasing the levels of free Gccs 
subunits. We previously noticed that stable expression of the 
rat H2 receptor in CHO cells not only enhanced the basal 
cAMP level but also potentiated the forskolin-induced 
cAMP production [18]. In this study, we provide evidence 
that the enhancement of the forskolin response is indeed the 
consequence of the constitutive activity of the wild-type H2 
receptor. We show that modulation of the forskolin response 
offers a useful method to investigate constitutive GPCR ac-
tivity in several cell lines and inverse agonism at wild-type Gs-
coupled receptors under normal experimental conditions. 
2. Materials and methods 
2.1. Chemicals 
Histamine dihydrochloride, isobutylmethylxanthine (IBMX), ami-
nopotentidine, cyclic AMP (cAMP), DEAE-dextran, chicken egg al-
bumin and forskolin were obtained from Sigma Chemical Company 
(USA). [2,8-3H]cAMP (40 Ci/mmol) was obtained from Amersham. 
VUF 8299 was taken from laboratory stock [19]. Gifts of cimetidine 
(SmithKline Beecham, United Kingdom), ranitidine dihydrochloride 
(Glaxo, United Kingdom) and famotidine (Merck Sharp and Dohme, 
The Netherlands) are greatly acknowledged. 
2.2. Cell culture and transfection 
Chinese Hamster ovary (CHO) cells deficient in dihydrofolate re-
ductase (CHOdhfr~), H2 receptor expressing CHO (CHOH2) and 
human embryonic kidney (HEK-293H2) cells, African green monkey 
kidney (COS-7) cells and SB insect cells were grown as described 
previously [20-22]. 
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COS-7 cells were transiently transfected with the expression vectors 
pSVL, pSVL-TSHI486F, pSVL-TSHF631L and pSVL-TSH (5 ug 
DNA/106 cells) using DEAE-dextran [23], Sf9 cells were infected 
with a recombinant baculovirus containing the epitope-tagged H2 
receptor as described by Beukers et al. [22]. 
2.3. Biochemical measurements 
The determination of H2 receptor binding with the H2 antagonist 
[125I]iodoaminopotentidine ([125I]APT) was performed as described by 
Leurs et al. [24]. The cAMP production in CHO, HEK-293, COS-7 
(48 h after transfection) and Sf9 cells was determined as described 
previously [18]. Protein concentrations were determined according to 
Bradford using bovine serum albumin as a standard [25]. 
2.4. Statistical analysis 
All data shown are expressed as mean ± standard error (mean± 
S.E.M.) of at least three independent experiments. Statistical analysis 
was carried out by Student's i-test. P-values < 0.05 were considered 
to indicate a significant difference. 
3. Results 
In CHOdhfr" cells, stably expressing the H2 receptor [24] at 
a density of 1079 ±313 fmol/mg protein (mean ± S.E.M., 
n = 6) (CHOH2 cells), the basal cAMP level was about 2-
fold higher (170 ±37 pmol cAMP/mg protein, mean 
± S.E.M., w = 6) than in CHOdhfr" cells (78 ±13 pmol 
cAMP/mg protein, mean ± S.E.M., ra = 6, P<0.05). Forskolin 
dose-dependently increased the cAMP formation in both 
CHOdhfr" and CHOH2 cells (Fig. 1). At each tested concen-
tration the forskolin-induced cAMP production in CHOH2 
cells was significantly higher than in CHOdhfr - cells. The 
absolute difference in cAMP production was maximal (1600 
pmol cAMP/mg protein) at a concentration of 1 u\M of for-
skolin. A potentiation of the forskolin response was also seen 
at higher concentrations of forskolin, but due to the increased 
response in the CHOdhfr - cells the relative increase was lower 
at these concentrations (Fig. 1). 
The inverse agonist cimetidine dose-dependently reduced 
the elevated basal cAMP level of CHOH2 cells to 52 ± 3% 
(mean ± S.E.M., n = 12) (Table 1). Cimetidine also inhibited 
the forskolin-induced cAMP production in CHOH2 cells, 
whereas in CHOdhfr - cells cimetidine did not exhibit any 
negative intrinsic activity (Fig. 2A). VUF8299, a cimetidine 
analogue with strongly reduced H2 receptor affinity [19], 
showed up to 10 u\M no negative intrinsic activity in CHOH2 
cells (Fig. 2B). The pICso values for cimetidine, as determined 
by inhibition of either the basal cAMP level or forskolin-in-
duced (1 or 10 uM) cAMP formation, were not significantly 
different (Table 1). Moreover, these values correspond with 
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Fig. 1. Forskolin-induced increase in cAMP production in untrans-
fected (open circles) and CHOH2 cells (filled circles). The data 
shown represent the mean ± S.E.M. of six experiments. The asterisk 
indicates a significant difference (P<0.05) compared to CHOdhfr" 
cells. 
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Fig. 2. A: Effect of cimetidine on forskolin-induced (10 uM) cAMP 
production in CHOdhfr" (open circles) and CHOH2 cells (filled 
circles). The data shown represent the mean ± S.E.M. of respectively 
four or eight experiments. B: Effect of cimetidine (filled circles) and 
the inactive analogue, VUF 8299 (open circles), on forskolin-in-
duced (10 uM) cAMP production in CHOH2 cells. The data shown 
represent the mean ± S.E.M. of respectively eight or six experiments. 
the observed pK¡ value of 6.2 ±0.2 (mean ± S.E.M., ra = 3), 
as determined from [125I]APT displacement studies. The per-
centage maximal inhibition by the inverse agonist decreased at 
higher concentrations of forskolin (Table 1), as expected from 
the data in Fig. 1. Besides cimetidine, ranitidine and famoti-
dine were also tested for their effect on the forskolin response 
in CHOH2 cells. The pIC5o values for these inverse agonists, 
determined by inhibition of the forskolin response, also cor-
respond well with the values determined by inhibition of the 
basal cAMP level (Table 2). The negative intrinsic activity 
(oiinv) of cimetidine determined by inhibition of the forskolin 
response in CHOH2 cells was significantly lower than that of 
famotidine and ranitidine (Table 2). At the basal cAMP level 
no significant differences in intrinsic activity of the inverse 
agonists were found (Table 2). 
The modulation of the forskolin response by constitutively 
active H2 receptors was not restricted to CHO cells. Stable 
expression of the H2 receptor in HEK-293 cells at a density of 
1594 ±17 fmol/mg protein [21] resulted in an approximately 
10-fold increase in the cAMP production induced by 10 |J,M 
forskolin (HEK-293 cells: 805 ±245 pmol/mg protein 
(mean±S.E.M., « = 6), HEK-293H2 cells: 7471 ±998 pmol/ 
Table 1 
The pIC5o and the maximal inhibitory response of cimetidine in 
CHOH2 cells determined on the basal cAMP level and forskolin-in-
duced cAMP formation 
Conditions pIC5, % inhibition 
Basal 
1 uM forskolin 
10 |xM forskolin 
6.3 ±0.2 
6.3±0.1 
6.0 ±0.2 
48 ±3 
41 ±2* 
36 ±2* 
12 
4 
The PIC50 and the maximal inhibition were determined from the in-
hibition curve of cimetidine. 
* indicates a significant difference (P < 0.05) from the % inhibition of 
the basal cAMP level. 
n, number of experiments. 
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Fig. 3. Effect of cimetidine (hatched bars) on basal and forskolin-in-
duced cAMP production in Sf9 cells expressing the H2 receptor. Sf9 
cells infected with recombinant baculovirus containing an epitope-
tagged H2 receptor were exposed to 100 uM cimetidine, in the pres-
ence or absence of 100 uM forskolin. Basal cAMP level in Sf9 cells 
expressing the H2 receptor: 10.5 ±3.9 pmol/106 cells. The data 
shown represent the mean ± S.E.M. of four experiments. The single 
asterisk indicates a significant difference (P<0.05). 
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Fig. 4. Basal (white bars) and forskolin-induced (10 u.M) cAMP 
production (hatched bars) in COS-7 cells transiently transfected 
with pSVL (C), pSVL-TSH (WT), pSVL-TSHI486F (I486F) and 
pSVL-TSHF631L (F631L). The data shown represent the data of a 
typical experiment, from three independent experiments, each per-
formed in triplicate. 
mg protein (mean ± S.E.M., n = 6)). The increase in the basal 
cAMP level was approximately 15-fold (HEK-293 cells: 33 ± 5 
pmol/mg protein (mean ± S.E.M., n = 6), HEK-293H2 cells: 
572 ±83 pmol/mg protein (mean ± S.E.M., w = 6)). The in-
crease in the forskolin response by the constitutive activity 
of the H2 receptor in HEK-293H2 cells was inhibited by ci-
metidine (pIC50 = 6.0±0.1, mean t S.E.M., « = 3). Further-
more, in previous studies we showed that the wild-type H2 
receptor can also be functionally expressed in insect Sf9 cells 
[22]. Infection of Sf9 cells with recombinant baculovirus re-
sulted in high expression levels of H2 receptor proteins (2.7 
pmol/mg protein). Expression of the H2 receptor did not sig-
nificantly elevate the basal cAMP level in Sf9 cells [22]. Yet, 
the response to 100 uM forskolin was enhanced after H2 
receptor expression (53 ±14 pmol cAMP/106 cells, 
mean ± S.E.M., M = 3 ) compared to mock-infected Sf9 cells 
(15 ±4 pmol cAMP/106 cells, mean t S.E.M., « = 3). Cimeti-
dine showed no significant effect on the basal cAMP produc-
tion in these cells (Fig. 3). However, a small, but significant, 
inhibition of the forskolin-induced (100 uM) cAMP produc-
tion by cimetidine was observed (Fig. 3). 
Finally, we transiently expressed the thyrotropin (TSH) re-
ceptor and the constitutively activated Ile486Phe and 
Phe631Leu TSH receptor mutants [26] in COS-7 cells. Expres-
sion of the wild-type receptor resulted in a small, but signifi-
cant elevation of the basal cAMP level compared to mock-
(pSVL) transfected COS-7 cells (Fig. 4). As reported previ-
ously [26], the two clinically important CAM TSH receptors 
both caused a marked elevation of the basal cAMP level. In 
the presence of forskolin the constitutive activity of the wild-
type TSH receptor became quite prominent and easy to detect 
in comparison to the minor increase in the basal cAMP level 
(Fig. 4). The constitutive activity of the two CAM receptors 
was further magnified (Fig. 4). 
4. Discussion 
In this study we show that the modulation of forskolin 
response by constitutively active Gs-coupled receptors offers 
a simple way to investigate inverse agonism at wild-type Gs-
coupled receptors. Stable expression of the H2 receptor in 
CHO cells both enhanced basal and forskolin-induced 
cAMP production, probably by increasing the level of free 
Gocs subunits. The increase in forskolin-induced cAMP pro-
duction was maximal at a concentration of 1 u.M. At higher 
forskolin concentrations the relative increase in forskolin-in-
duced cAMP production decreased due to the increased re-
sponse in CHOdhfr cells. If the increase in forskolin-induced 
cAMP production is a direct effect of the constitutive activity 
of the H2 receptor, inverse agonists should, as shown at the 
basal cAMP level [18], be able to inhibit the H2 receptor-
mediated increase of the forskolin-induced cAMP production. 
Indeed, a dose-dependent inhibition of the forskolin-induced 
cAMP production by cimetidine was observed. As expected, 
the maximal inhibition by cimetidine in CHOH2 cells was 
slightly higher at a forskolin concentration of 1 uM than at 
a concentration of 10 u.M. The pICso values of cimetidine 
determined from the inhibition of the forskolin responses 
were not significantly different from the values determined 
from the inhibition of the basal cAMP level (Table 1). In 
addition, investigation of the inverse agonistic properties of 
famotidine and ranitidine in CHOH2 cells revealed no signifi-
cant differences in inverse agonistic behaviour determined in 
either the absence or presence of forskolin (Table 2). Modu-
lation of the forskolin response by constitutively active H2 
receptors thus represents a useful tool to study inverse ago-
nism at the H2 receptor. The method seems quite sensitive as 
in CHOH2 cells cimetidine could be classified as a partial 
inverse agonist at forskolin-stimulated cAMP levels. At the 
Table 2 
PIC50 and dim of different inverse agonists in CHOH2 cells determined on the basal cAMP level and forskolin-induced cAMP formation 
Drug 
Cimetidine 
Famotidine 
Ranitidine 
Basal 
pIC6o 
6.3 ±0.2 
6.7 ±0.2 
6.8 ±0.2 
Otinv 
0.88 ± 0.04 
0.88 ±0.05 
1.00 ±0.03 
Forskolin 
pIC6o 
6.3 ±0.1 
6.7 ±0.3 
6.7 ±0.3 
( l u M ) 
Otinv 
0.83 ± 0.02* 
0.93 ± 0.04 
1.00 ±0.02 
PIC50 and the a-mv were determined from the inhibition curve of the indicated drug on either the basal cAMP level or the forskolin-induced cAMP 
production. The data shown represent the mean ± S.E.M. of three independent experiments performed in duplicate. 
* indicates a significant difference (P < 0.05) from a-mY of ramtidine which caused a maximal inhibition in this cell line. 
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basal cAMP level no differences in negative intrinsic activity 
(0Cjnv) between cimetidine, famotidine and ranitidine could be 
detected. This is probably due to the fact that the forskolin-
induced cAMP levels are about 20-fold higher than basal 
cAMP levels and small differences can consequently be de-
tected easier. 
The increase of the forskolin response by H2 receptor ex-
pression is not limited to a particular cell type. Compared to 
CHOH2 cells the constitutive activity of the H2 receptor was 
more pronounced in HEK-293 cells. Stable expression of the 
H2 receptor in this cell line resulted in a strongly enhanced 
basal and forskolin-induced cAMP production, that was in-
hibited by the inverse agonist cimetidine with comparable po-
tency as observed in CHOH2 cells. In insect Sf9 cells the H2 
receptor is not very efficiently coupled to adenylyl cyclase 
activation [22]. Consequently, in these cells no inverse ago-
nism by cimetidine could be detected at the basal cAMP level. 
Nevertheless, this inverse agonist was able to decrease the 
forskolin-induced cAMP production in Sf9 cells expressing 
the H2 receptor. These data further support the high sensitiv-
ity of the described method to measure inverse agonism. 
Importantly, transient expression of the Gs-coupled TSH 
receptor and constitutively active TSH mutant receptors [26] 
in COS-7 cells also modulated the forskolin response. A clear 
constitutive activity of the wild-type TSH receptor was ob-
served after evaluation of the forskolin responses. Our method 
to study inverse agonism at the H2 receptor may thus be of 
general use in the study of inverse agonism at Gs-coupled 
receptors. Further evidence supporting this suggestion is avail-
able in literature [27-29]. Takuma et al. [29] showed e.g. that 
propranolol reduces the forskolin response in rat parotid ati-
nar cells endogenously expressing the ßi receptor. This inhib-
ition was not attributed to inverse agonism as this phenom-
enon was relatively new at that moment. From experimental 
data obtained with heterologous expression systems and/or 
CAM receptors, the modulation of the forskolin response 
by constitutively active Gs-coupled receptors can often be 
deduced [30,31]. In line with our findings, constitutively active 
G¡-coupled receptors also affect forskolin response [32,33]. As 
expected, the forskolin response is modulated in a way oppo-
site to that of Gs-coupled receptors and consequently the el-
evation of the forskolin response by inverse agonists can be 
regarded as a related assay for inverse agonism at G¡-coupled 
receptors [32,33]. 
In conclusion, we observed that constitutively active Gs-
coupled receptors (H2 and TSH receptor) not only enhance 
basal cAMP production but also increase the forskolin re-
sponse in a variety of cell lines (CHO, HEK-293, COS-7 
and Sf9 cells). Inverse agonists are able to reduce the in-
creased forskolin response. Thorough investigation of the in-
verse agonistic properties of cimetidine, famotidine and rani-
tidine in CHOH2 cells revealed no significant differences in 
inverse agonistic potency determined in either the absence or 
presence of forskolin. Inhibition of forskolin responses may 
thus be very useful to investigate inverse agonism at wild-type 
receptors and eliminate the need of using CAM receptors. 
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